While anemia impacts nearly a quarter of the world's population, the prevalence of iron deficiency may be twice as high, ...

It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.

Q: I have Type 2 diabetes. My doctor tells me that I can improve my health if I cut out carbs and eat a keto diet. Is that ...

Sickle cell anemia requires ongoing, lifelong treatment to improve quality of life and prevent complications. Treatment of sickle cell anemia includes taking measures to treat anemia, prevent ...

We're always interested in hearing about news in our community. Send us your news, photos, and videos and let us know what's going on!

Sickle Cell Disease (SCD) refers to a group of inherited blood disorders that cause red blood cells to become stiff and crescent-shaped ... common symptom of SCD is anemia, which can lead to ...

Normal red blood cells are round and flexible, allowing smooth travel through blood vessels, but sickle cell disease causes them to form a rigid, crescent ... sickle cell anemia (SCA), the ...

or sickle cell anemia. But having sickle cell trait raises the risk of some health conditions. According to the American Society of Hematology, between 1 million and 3 million Americans have ...

In people with SCD, the red blood cells, which are typically round and flexible, become crescent-shaped ... People with sickle cell disease often experience a variety of symptoms and complications, ...

Following closing, the combined company will advance Crescent’s portfolio of precision ... of the role that carbohydrates play in cell recognition. Its specialized chemistry platform can be ...

Following closing, the combined company will advance Crescent’s portfolio of precision-engineered biologics to improve outcomes for patients with solid tumors Crescent’s lead program CR-001 ...

Crescent Biopharma has landed a Nasdaq listing in a reverse merger with GlycoMimetics and secured $200 million to support its pursuit of the white-hot PD-1xVEGF bispecific opportunity ...